BioSpace News Archive

Guardant Health, Inc., along with leading academic institutions and pharmaceutical companies, share data highlighting molecular targets of importance, treatment resistance patterns, and advantages of using the Guardant360® liquid biopsy test to help improve the management of advanced solid cancers at the European Society for Medical Oncology 2021 virtual congress on September 16-21.

Dental prostheses can be immediately placed on replacement teeth with highly predictable outcomes during jaw reconstruction that involves taking bone from the patient’s leg, a new study finds.

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that it will be participating at upcoming conferences.

Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that the U.S. Food and Drug Administration has granted Fast Track Designation to SAGE-718 for development as a potential treatment for Huntington’s disease.

Indaptus Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Company’s platform technology.

Ms. Barnett brings a wealth of financial experience to Immunovant Expands executive leadership team as Immunovant plans to return to the clinic across multiple indications

Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection

U.S. FDA Grants BRUKINSA ® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma

Ivantis to Pay $60 Million and Ongoing Double-Digit Royalty to Glaukos

Spinal Elements ® Announces Full Commercial Launch of Luna ® XD and Orbit ™ Systems